Xarelto and Eliquis Squaring Off

Eliquis® vs. Xarelto® & Pradaxa®
The latest financial reports of billion dollar pharmaceutical behemoths Bristol Myers Squib and Johnson & Johnson have me concerned. The competition to be first in the marketplace for new age blood thinners, commonly known as anti-coagulants, is heating up. Bristol Myers Squib’s Elliquis® and Johnson & Johnson’s Xarelto® are locked in a battle for supremacy.

The winner will reap billions of dollars in profits in the coming years. These billions of dollars come at the expense of who and what? In my view, the lives of the patients prescribed Elliquis® and Xarelto® are the expense.

Xarelto® is a once daily pill that hit the market in 2011 to treat deep vein thrombosis (DVT) in joint replacement patients. It has since been approved to reduce the possibility of strokes and pulmonary embolism. In 2014, Johnson & Johnson reported that sales of the drug reached $1.5 billion. Television commercials costing $12 million with golfer Arnold Palmer, comedian Kevin Nealon, and NASCAR driver Brian Vickers no doubt helped sales.

Elliquis® is a twice daily pill approved in late 2012 by the FDA solely to lessen the risk of stroke. Xarelto® and Pradaxa® dominated the market until Elliquis® was approved for similar treatments as those brands. Elliquis® had $146 million in sales for 2013. That number rose to $774 million in 2014.

New Age Anti-Coagulant Sales Could Be Higher
It is estimated that more than $10 billion is spent per year in the US for anti-coagulants. Much of that number is for sales of Coumadin, which is generically known as warfarin. The main reason that Xarelto® and Elliquis® do not account for more sales is there is no way to stop a patient from bleeding while on those drugs. This lack of antidote has already led the manufacturer of Pradaxa®, another new age blood thinner, to pay out millions of dollars to people injured or killed by that drug.

While not all people suffer bad bleeding events on Xarelto® and Eliquis®, it should be enough that some people do. Plain and simple, there is no way to stop the bleeding caused by these new age anti-coagulants. Yet, they still remain on the market being sold to millions of people worldwide. The only way the public will know of the dangers of these drugs is by people hurt coming forward. The Parian Law Firm, LLC stands ready to let the world know about dangerous drugs such as Xarelto® and Eliquis®.

We Represent Clients Nationwide Against Xarelto® | Eliquis® |Pradaxa®
The Atlanta GA Dangerous Drugs Lawyers of The Parian Law Firm, LLC help people injured by the false marketing and failures to warn by the billion dollar pharmaceutical companies. A unified front of some of America’s best trial lawyers go to battle for you. Don’t sit and suffer. Let us fight back for you.

We are currently accepting clients injured by the following drugs:

Xarelto® and Johnson & Johnson are currently the subject of litigation in Louisiana for harming patients on the drug. The Parian Law Firm, LLC continues to review claims each day by patients suffering bleeds while taking Xarelto®. If you or a loved one suffered a bleeding event that required you to seek medical care while you were on Xarelto®, call us at (770) 727-5550 to discuss the situation.
Eliquis® and Bristol Myers Squib are not currently involved in litigation; however, The Parian Law Firm, LLC is reviewing claims from patients who suffered a bleeding event that required medical treatment while on Eliquis®. Call us at (770) 727-5550 to discuss your matter.
Pradaxa® and Boeringer Ingelheim settled more than 4,000 claims in May 2014 for $650 million. Yet, Pradaxa® remains on the market being sold to millions of people. The Parian Law Firm, LLC continues to review claims from people that suffered bleeds that required a hospital stay and blood transfusion while on Pradaxa®. Call us at (770) 727-5550.